Innovation | Novartis United States of America

Media Release
Dec 16, 2014
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Media Release
Dec 16, 2014
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Media Release
Dec 06, 2014
Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
Media Release
Nov 17, 2014
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients
Media Release
Nov 16, 2014
Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
Media Release
Nov 15, 2014
Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies
Media Release
Nov 10, 2014
Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Media Release
Oct 21, 2014
Novartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™
Media Release
Oct 20, 2014
Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis
Media Release
Oct 15, 2014
Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)
Media Release
Sep 27, 2014
Novartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
Media Release
Aug 30, 2014
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

‹ Previous page
1
…
18
19
20
21
22
23
24
…
50
› Next page